Item 8.01 Other Events.

On February 7, 2023, Anavex Life Sciences Corp., a Nevada corporation (the "Company") filed a prospectus supplement with the Securities and Exchange Commission to the Company's Shelf Registration Statement on Form S-3ASR (File No. 333-259788) registering shares of the Company's common stock, par value $0.001 per share (the "Shares"), issuable pursuant to its purchase agreement dated February 3, 2023 with Lincoln Park Capital Fund, LLC (the "Purchase Agreement"). Snell & Wilmer, L.L.P., special counsel to the Company, has issued a legal opinion relating to the Shares issuable under the Purchase Agreement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits.






  (d)  Exhibits




EXHIBIT NO.     DESCRIPTION                             LOCATION
5.1               Opinion of Snell & Wilmer, L.L.P.     Filed herewith
23.1              Consent of Snell & Wilmer, L.L.P.     Contained in Exhibit 5.1
                                                        (embedded within the Inline XBRL
104             Cover Page Interactive Data File        document)

© Edgar Online, source Glimpses